Biota Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 81   

Articles published

BOTA 2.44 +0.04 (1.67%)
price chart
Biota Pharmaceuticals Inc Stock Downgraded (BOTA)
The gross profit margin for BIOTA PHARMACEUTICALS INC is currently lower than what is desirable, coming in at 34.92%. It has decreased significantly from the same period last year.
Related articles »  
Biota Pharmaceuticals: An Undervalued Long-Term Influenza Play (BOTA)
Biota is reducing headcount by 69% between June 2014 and June 2015, as well as closing its Melbourne facility, significantly decreasing cash burn.
Biota Pharmaceuticals to Host Conference Call to Report First Quarter ...
ATLANTA, Oct. 28, 2014 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) ("Biota" or the "Company") announced today that management will host a conference call on Friday, November 7, 2014 at 9:00 a.m.
Related articles »  
Biota Pharmaceuticals Inc. And Venaxis Inc.: 2 Upcoming Biopharmaceuticals ...
Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) is a biopharmaceutical company focused on the discovery and development of anti-infective products to prevent and treat a number of serious and potentially life-threatening infectious diseases.
Biota Pharmaceuticals relos HQ to Atlanta
Rockville, Md.-based Biota Pharmaceuticals, Inc. [NASDAQ: BOTA] focuses on the development of anti-infective products to prevent and treat potentially life-threatening viral and bacterial infectious diseases, such as respiratory syncytial virus disease ...
Biota Pharmaceuticals to Make Alpharetta, GA Its New Home  GPB (blog)
Related articles »  
Mid-Day Changers: US Energy Corp. (USEG), Biota Pharmaceuticals, Inc ...
Biota Pharmaceuticals, Inc. (BOTA) of the Healthcare sector (Biotechnology) has gained 2.92% per share at mid-day today.
Related articles »  
Massive Swings: Biota Pharmaceuticals, Inc. and Amicus Therapeutics, Inc.
Healthcare investors were presented with major movements in two small stocks today: Amicus Therapeutics (NASDAQ: FOLD ) popped almost 21% on strong phase 3 data for a Fabry disease drug, while Biota Pharmaceuticals (NASDAQ: BOTA ) collapsed ...
Related articles »  
Biota Pharmaceuticals Reports Fourth Quarter and Fiscal Year-End 2014 ...
ATLANTA, Sept. 26, 2014 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company") today announced financial results for its fourth quarter and fiscal year ended June 30, 2014, and provided an update on a number of recent ...
Related articles »  
34% Drop in Biota Pharmaceutical, Inc.'s Stock Price: Law Firm Investigates on ...
SAN DIEGO and NEW YORK, May 12, 2014 /PRNewswire/ -- Shareholder rights law firm Robbins Arroyo LLP is investigating potential violations of federal securities laws on behalf of investors of Biota Pharmaceutical, Inc. BOTA, -1.23% Biota ...
Related articles »  
Biota Pharmaceuticals Reports First Quarter Fiscal Year 2015 Financial Results
ATLANTA, Nov. 7, 2014 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company") today announced its financial results for the three month period ended September 30, 2014, which is the first quarter of the Company's 2015 fiscal ...
Related articles »